Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1995 Nov;40(5):467–476. doi: 10.1111/j.1365-2125.1995.tb05791.x

Patterns of drug treatment of schizophrenic patients in Estonia, Spain and Sweden.

R A Kiivet 1, A Llerena 1, M L Dahl 1, L Rootslane 1, J Sánchez Vega 1, T Eklundh 1, F Sjöqvist 1
PMCID: PMC1365193  PMID: 8703651

Abstract

1. Patterns of drug treatment and the use of polypharmacy in schizophrenic in-patients were compared and evaluated in the University Teaching Hospitals of Psychiatry in Badajoz, Spain, Huddinge, Sweden, and Tartu, Estonia. 2. The medical records of up to 100 consecutively admitted patients were retrospectively reviewed using a standardized data form. 3. The male patients were significantly younger than females in all study locations, but there were no age differences between the locations. The length of stay was equal for the two series in the same hospital, but considerably longer in Tartu than in Badajoz and Huddinge. 4. The neuroleptic drugs used most commonly in Badajoz and Tartu were similar in prescription frequency and in the doses prescribed, but different from those used in Huddinge. Haloperidol was the most frequently prescribed neuroleptic in Badajoz and Tartu, accounting for one third of all neuroleptic prescriptions. In Huddinge the choice of neuroleptics was more evenly spread over several compounds. Intramuscular injections other than depot preparations were commonly used in Tartu and Badajoz, but not in Huddinge. 5. At least two neuroleptics were prescribed simultaneously on 73% of treatment days in Badajoz and 46% in both Huddinge and Tartu. The average cumulative daily doses of concomitant multiple neuroleptic treatment, expressed in chlorpromazine equivalents, were lower in Huddinge than in the other study locations and higher for male patients in Badajoz and Tartu. 6. Anticholinergics were used together with neuroleptics in 42% of treatment days in Badajoz and 30% in Huddinge as compared with 75% in Tartu. The use of anticholinergics increased in parallel to the increase in the number and the cumulative dose of concomitant neuroleptics in all study locations. 7. About 15% of patients in Badajoz and Tartu, but only 1% in Huddinge, received concomitant treatment with antidepressant drugs. The simultaneous use of antidepressants and benzodiazepines was inversely related to the number and the cumulative dose of neuroleptics in Badajoz and Tartu. In contrast, the cumulative dose and number of neuroleptics were greater, when additional benzodiazepines were prescribed in Huddinge. 8. The study in schizophrenic in-patients revealed that polypharmacy with concomitant multiple neuroleptics, additional anticholinergics and other psychotropics is an international phenomenon.

Full text

PDF
467

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baldessarini R. J., Cohen B. M., Teicher M. H. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry. 1988 Jan;45(1):79–91. doi: 10.1001/archpsyc.1988.01800250095013. [DOI] [PubMed] [Google Scholar]
  2. Baldessarini R. J., Davis J. M. What is the best maintenance dose of neuroleptics in schizophrenia? Psychiatry Res. 1980 Oct;3(2):115–122. doi: 10.1016/0165-1781(80)90028-1. [DOI] [PubMed] [Google Scholar]
  3. Baldessarini R. J., Katz B., Cotton P. Dissimilar dosing with high-potency and low-potency neuroleptics. Am J Psychiatry. 1984 Jun;141(6):748–752. doi: 10.1176/ajp.141.6.748. [DOI] [PubMed] [Google Scholar]
  4. Brayley J., Rafalowicz E., Yellowlees P. Psychotropic drug prescribing in a general hospital inpatient psychiatric unit. Aust N Z J Psychiatry. 1989 Sep;23(3):352–356. doi: 10.3109/00048678909068292. [DOI] [PubMed] [Google Scholar]
  5. Brøsen K., Gram L. F. Clinical significance of the sparteine/debrisoquine oxidation polymorphism. Eur J Clin Pharmacol. 1989;36(6):537–547. doi: 10.1007/BF00637732. [DOI] [PubMed] [Google Scholar]
  6. Chiu H. F., Shum P. S., Lam C. W. Psychotropic drug prescribing to chronic schizophrenics in a Hong Kong hospital. Int J Soc Psychiatry. 1991 Autumn;37(3):187–191. doi: 10.1177/002076409103700305. [DOI] [PubMed] [Google Scholar]
  7. Dahl M. L., Bertilsson L. Genetically variable metabolism of antidepressants and neuroleptic drugs in man. Pharmacogenetics. 1993 Apr;3(2):61–70. doi: 10.1097/00008571-199304000-00001. [DOI] [PubMed] [Google Scholar]
  8. Davis J. M. Comparative doses and costs of antipsychotic medication. Arch Gen Psychiatry. 1976 Jul;33(7):858–861. doi: 10.1001/archpsyc.1976.01770070088010. [DOI] [PubMed] [Google Scholar]
  9. Der G., Gupta S., Murray R. M. Is schizophrenia disappearing? Lancet. 1990 Mar 3;335(8688):513–516. doi: 10.1016/0140-6736(90)90745-q. [DOI] [PubMed] [Google Scholar]
  10. Griffiths K., McDevitt D. G., Andrew M., Baksaas I., Helgeland A., Jervell J., Lunde P. K., Oydvin K., Agenäs I., Bergman U. Therapeutic traditions in Northern Ireland, Norway and Sweden: I. Diabetes. WHO Drug Utilization Research Group (DURG). Eur J Clin Pharmacol. 1986;30(5):513–519. doi: 10.1007/BF00542408. [DOI] [PubMed] [Google Scholar]
  11. Griffiths K., McDevitt D. G., Andrew M., Baksaas I., Helgeland A., Jervell J., Lunde P. K., Oydvin K., Agenäs I., Bergman U. Therapeutic traditions in Northern Ireland, Norway and Sweden: II. Hypertension. WHO Drug Utilization Research Group (DURG). Eur J Clin Pharmacol. 1986;30(5):521–525. doi: 10.1007/BF00542409. [DOI] [PubMed] [Google Scholar]
  12. Holloway F. Prescribing for the long-term mentally ill. A study of treatment practices. Br J Psychiatry. 1988 Apr;152:511–515. doi: 10.1192/bjp.152.4.511. [DOI] [PubMed] [Google Scholar]
  13. Johnson D. A., Wright N. F. Drug prescribing for schizophrenic out-patients on depot injections. Repeat surveys over 18 years. Br J Psychiatry. 1990 Jun;156:827–834. doi: 10.1192/bjp.156.6.827. [DOI] [PubMed] [Google Scholar]
  14. Kessler K. A., Waletzky J. P. Clinical use of the antipsychotics. Am J Psychiatry. 1981 Feb;138(2):202–209. doi: 10.1176/ajp.138.2.202. [DOI] [PubMed] [Google Scholar]
  15. Kiivet R. A., Bergman U., Sjöqvist F. The use of drugs in Estonia compared to the Nordic countries. Eur J Clin Pharmacol. 1992;42(5):511–515. doi: 10.1007/BF00314860. [DOI] [PubMed] [Google Scholar]
  16. Laska E., Varga E., Wanderling J., Simpson G., Logemann G. W., Shah B. K. Patterns of psychotropic drug use for schizophrenia. Dis Nerv Syst. 1973 Aug-Sep;34(6):294–305. [PubMed] [Google Scholar]
  17. Mehtonen O. P., Aranko K., Mälkonen L., Vapaatalo H. A survey of sudden death associated with the use of antipsychotic or antidepressant drugs: 49 cases in Finland. Acta Psychiatr Scand. 1991 Jul;84(1):58–64. doi: 10.1111/j.1600-0447.1991.tb01421.x. [DOI] [PubMed] [Google Scholar]
  18. Reardon G. T., Rifkin A., Schwartz A., Myerson A., Siris S. G. Changing patterns of neuroleptic dosage over a decade. Am J Psychiatry. 1989 Jun;146(6):726–729. doi: 10.1176/ajp.146.6.726. [DOI] [PubMed] [Google Scholar]
  19. Rifkin A., Doddi S., Karajgi B., Borenstein M., Wachspress M. Dosage of haloperidol for schizophrenia. Arch Gen Psychiatry. 1991 Feb;48(2):166–170. doi: 10.1001/archpsyc.1991.01810260074011. [DOI] [PubMed] [Google Scholar]
  20. Rosholm J. U., Hallas J., Gram L. F. Concurrent use of more than one major psychotropic drug (polypsychopharmacy) in out-patients--a prescription database study. Br J Clin Pharmacol. 1994 Jun;37(6):533–538. doi: 10.1111/j.1365-2125.1994.tb04300.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Volavka J., Cooper T., Czobor P., Bitter I., Meisner M., Laska E., Gastanaga P., Krakowski M., Chou J. C., Crowner M. Haloperidol blood levels and clinical effects. Arch Gen Psychiatry. 1992 May;49(5):354–361. doi: 10.1001/archpsyc.1992.01820050018002. [DOI] [PubMed] [Google Scholar]
  22. Wilson W. H., Ban T. A., Guy W. Pharmacotherapy of chronic hospitalized schizophrenics: prescription practices. Neuropsychobiology. 1985;14(2):75–82. doi: 10.1159/000118208. [DOI] [PubMed] [Google Scholar]
  23. Wysowski D. K., Baum C. Antipsychotic drug use in the United States, 1976-1985. Arch Gen Psychiatry. 1989 Oct;46(10):929–932. doi: 10.1001/archpsyc.1989.01810100071013. [DOI] [PubMed] [Google Scholar]
  24. van Os J., Galdos P., Lewis G., Bourgeois M., Mann A. Schizophrenia sans frontieres: concepts of schizophrenia among French and British psychiatrists. BMJ. 1993 Aug 21;307(6902):489–492. doi: 10.1136/bmj.307.6902.489. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES